HCW Biologics Inc
Company Profile
Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
Contact
2929 N. Commerce Parkway
MiramarFL33025
USAT: +1 954 842-2024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
35
Stocks News & Analysis
stocks
Margins have bottomed for ASX listed consumer goods company
stocks
SpaceX rally continues, expanding sky-high valuations
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,031.20 | 9.40 | 0.10% |
| CAC 40 | 8,401.27 | 19.87 | -0.24% |
| DAX 40 | 25,137.12 | 151.30 | 0.61% |
| Dow JONES (US) | 51,826.00 | 261.30 | 0.51% |
| FTSE 100 | 10,430.40 | 67.13 | 0.65% |
| HKSE | 23,768.52 | 156.29 | -0.65% |
| NASDAQ | 26,488.54 | 29.39 | -0.11% |
| Nikkei 225 | 72,353.96 | 1,103.90 | 1.55% |
| NZX 50 Index | 13,446.05 | 49.58 | -0.37% |
| S&P 500 | 7,519.53 | 18.95 | 0.25% |
| S&P/ASX 200 | 8,816.10 | 14.20 | 0.16% |
| SSE Composite Index | 4,163.10 | 72.62 | 1.78% |